Wellcome Funds UK Regulators to Build an AI Testing Sandbox for Mental Health Apps
- Wellcome has granted MHRA and NICE £2 million to extend their joint programme regulating digital mental health technology (DMHT) through autumn 2028.
- The centerpiece of the new phase is an "AI airlock" – a regulatory sandbox where AI tools that assess psychiatric risk from a user's responses can be tested with the regulator before reaching the NHS market.
- The programme builds on a first £1.8 million tranche running since 2023, which produced MHRA's DMHT qualification and classification guidance (Class I/IIa/IIb/III by diagnostic or treatment function) and an adverse event reporting framework for these products.
- Alongside the airlock, the new funding covers work on international recognition of DMHT regulatory decisions and on strengthening the UK evidence base for these technologies.
Computational psychiatry has spent a decade sharpening a vocabulary for what goes wrong in mental illness – prediction error, precision-weighting, hierarchical inference. None of that vocabulary appears in this funding announcement. What Wellcome is paying for is the much blunter, much more immediate category of software that flags psychiatric risk from how a user answers questions on a phone.
Following an Existing Blueprint
The £2 million is a continuation grant, not a new programme. MHRA and NICE have run this DMHT partnership since 2023 on a first £1.8 million tranche, and the deliverables so far are administrative rather than diagnostic: a classification scheme that sorts apps and AI tools into medical-device risk classes, and a reporting mechanism for when they cause harm. The 2028 extension adds the "AI airlock," which lets a developer test an AI diagnostic tool against regulatory criteria before it reaches patients, rather than after.
Cleared at Home, Untested Abroad
What the airlock does not resolve is portability. A tool cleared through UK testing produces evidence that is, for now, only as good as the UK's willingness to recognize it. The announcement flags international recognition as a separate, unfinished strand of work, not a solved problem.
The Boundary of What Got Funded
For anyone tracking whether computational or digital biomarkers will get a regulatory lane of their own, distinct from symptom-based AI screening, this funding round has a narrow answer. It covers gross classification and market access. It says nothing about how evidence travels once a marker crosses a border.
Regulators are building a faster lane for AI risk-screening tools, not a separate track for the computational biomarkers that gave the field its name.
This is a UK regulatory funding announcement, not a computational psychiatry study – "prediction error" and related constructs appear nowhere in the source, and the piece treats AI mental health screening broadly rather than any specific computational biomarker. The regulatory scope is UK-specific, though the international recognition question it raises is not. The funding is a time-limited grant from a charitable foundation, not a permanent budget line. The £1.8 million first-tranche figure and the DMHT classification guidance are drawn from MHRA and NICE's 2022 press release and their separate "qualification and classification" publication, both linked from the same GOV.UK collection as this announcement rather than stated in the November 2025 release itself.